Supporting information for

IL-7 promotes mRNA vaccine-induced long-term immunity

Lingli Wang^{1,2,3,4,5}, Jiawu Wan^{1,2,3,4,5}, Wenna He^{1,2,3,4}, Zongmei Wang^{1,2,3,4}, Qiong Wu^{1,2,3,4}, Ming Zhou^{1,2,3,4}, Zhen F. Fu^{1,2,3,4}, Ling Zhao^{1,2,3,4,6,*}

¹National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China

²Hubei Hongshan Laboratory, Wuhan 430070, China

³Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan 430070, China

⁴Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China

⁵These authors contributed equally

⁶Lead contact

*Correspondence: Ling Zhao, zling604@outlook.com, lingzhao@mail.hzau.edu.cn

This file includes: Fig. S1 to S7



Figure S1. The quality and expression of the in vitro-transcribed mRNA. (A) The capillary electropherograms and agarose gel electropherograms of G mRNA. (B) The capillary electropherograms and agarose gel electropherograms of IL-7 mRNA. (C) HEK-293T cells were transfected with LNP-encapsulated G mRNA (1 μ g), IL-7 mRNA (1 μ g) or G&IL-7 mRNA (1 μ g G mRNA + 1 μ g IL-7 mRNA). After 24 hours, ELISA was performed to measure the expression levels of G and IL-7 in the cell lysates (n = 3).



Figure S2. Different encapsulation strategies of IL-7 mRNA as an adjuvant. Mice were immunized using two different mRNA encapsulation methods: G mRNA and IL-7 mRNA were either coencapsulated in the same lipid nanoparticle (LNP) for injection or separately encapsulated in individual LNPs and then mixed prior to injection. Virus-neutralizing antibody (VNA) titers were assessed using fluorescent antibody virus neutralization (FAVN) assays (n = 5).



Figure S3. Expression levels of key genes and proteins in the JAK-STAT signaling pathway in mRNA vaccine-immunized and control mice. (A) The mRNA expression levels of JAK1, STAT5A, STAT5B, SOCS1, and SOCS3 in the inguinal lymph nodes (LNs) of mice (n = 7) inoculated with G mRNA and G&IL-7 mRNA. (B) The LNs from mice (n = 3) inoculated with G mRNA, G&IL-7 mRNA, and PBS were collected and homogenized. Western blotting was performed to assess the expression levels of JAK1, phosphorylated JAK1 (p-JAK1), STAT5, and phosphorylated STAT5 (p-STAT5).



Figure S4. Flow cytometry gating strategy for the detection of Tfh cells, GC B cells and PCs. (A) Gating strategy to identify Tfh cells (CD4⁺CXCR5⁺PD1⁺). (B) Gating strategy to identify GC B cells (B220⁺GL7⁺CD95⁺). (C) Gating strategy to identify PCs (B220^{low}CD138⁺).



Figure S5. Flow cytometry gating strategy for the detection of MBCs. Gating strategy to identify MBCs (B220⁺IgD⁻CD273⁺CD38⁺).



Figure S6. Safety evaluation of G&IL-7 mRNA. Vaccination of C57BL/6 mice via intramuscular injection with G mRNA, G&IL-7 mRNA or PBS, respectively. (A) Cytokine levels in the serum samples from mice were detected (n = 5). (B) The biochemical indicators of mice were analyzed using an automated hematological biochemical analyzer (n = 5). (C) Hematoxylin and eosin (H&E) staining was conducted on the major organs of mice on day 2. Scale bars represent 200 µm.



Figure S7. IL-7 mRNA concentration screening as an adjuvant for SARS-CoV-2 mRNA vaccine. Mice were immunized with S mRNA encapsulated alongside varying concentrations of IL-7 mRNA. Neutralizing antibodies against the original Wuhan strain were assessed using a pseudovirus neutralization assay (n = 5).